Allovir Inc reports results for the quarter ended in December - Earnings Summary

Kalaris Therapeutics

15/02/2023 13:38

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 37
cents​​ per share for the quarter ended in December. The mean
expectation of four analysts for the quarter was for a loss
of 54 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 37
cents​.
    * The mean earnings estimate of analysts had risen by
about 8.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Allovir Inc shares had risen by 28.3% this quarter.
    * The company reported a quarterly loss of $38.14 million.
    * Wall Street's median 12-month price target for Allovir Inc
is
$21.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
15 at 01:38 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.54          -0.37          Beat
 Sep. 30 2022      -0.53          -0.50          Beat
 Jun. 30 2022      -0.73          -0.69          Beat
 Mar. 31 2022      -0.80          -0.69          Beat